Skip to main content
. Author manuscript; available in PMC: 2019 Oct 31.
Published in final edited form as: J Am Coll Cardiol. 2019 Oct 15;74(15):1910–1923. doi: 10.1016/j.jacc.2019.07.081

Figure 4. Dabigatran treatment prevented fibrin deposition in the AD brain.

Figure 4.

Fibrin was extracted from the cortex/hippocampus of 30- and 60-week-old TgCRND8 AD and WT mice treated with dabigatran/placebo. (A) Equal amounts of the fibrin-containing fraction were pooled and subjected to WB using a specific fibrin(ogen) antibody (top panel), and then re-probed with a tubulin antibody as loading control (bottom panel). An in vitro fibrin clot was used as positive control (+). (B) The amount of the fibrin β-chain (double arrow) and tubulin were quantified in 8 different WBs, averaged, and plotted. Fibrin content in the brain increased with age and AD pathology, but dabigatran treatment prevented brain fibrin deposition in 60-week-old AD mice. Graph shows mean±SEM. Effect of treatment (p<0.0001) and age (p<0.0001) are significant. **p≤0.01 AD/60w/placebo vs. AD/60w/dabigatran. n=5-11 mice/group. Abbreviations as in Figure 1.